Monday, March 04, 2013 9:38:58 AM
~ANTB $1.72 DD...
I have been looking at more BIO plays over the last 3 months, here's one that looks to have nice potential in a huge market imo...
~Business Description:
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Our development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. Our lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
~Corporate web site:
http://antriabio.com/
~Share structure:
Number of shares of issuer’s common stock outstanding as of February 12, 2013: 40,000,000
Approximate float...5 million
~Chart:
Right near the historical low, looks like a potental move back over $2.25 based on this chart imo,
~About the lead diabetes product:
AntriaBio’s lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.
The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.
AB101’s long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.
After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.
In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.
~Pipeline:
In addition to the proprietary technology for PEGylation of insulin (AB101), AntriaBio plans to use proprietary microparticle manufacturing technology for a variety of opportunities across multiple indications.
~Recent News:
http://ir.stockpr.com/antriabio/company-news
Looks like they did a reverse merger with a forward split which is why the chart has a limited history,
~ AntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge With a Public Company
Jan 7, 2013, 9:00 AM EST
~ AntriaBio Completes Merger and Elects Board of Directors
Feb 6, 2013, 1:10 PM EST
~AntriaBio Announces Stock Ticker Symbol Change to ANTB
Feb 8, 2013, 10:44 AM EST
~AntriaBio Appoints Two Industry Leaders to Its Management Team
Feb 19, 2013, 10:37 AM EST
~Management team:
Nevan Elam, President and CEO
Mr. Elam joined the company in June 2012 and he is a Managing Director of Konus Advisory Group, a boutique healthcare firm. Mr. Elam has also been CEO of a surgical medical device company based in Europe since 2009 and prior to that he ran the Pulmonary Business Unit of Nektar Therapeutics which he sold to Novartis in 2008. Mr. Elam has spent his entire career starting, managing and advising emerging growth companies. Earlier in his career he was a corporate partner with Wilson Sonsini Goodrich & Rosati and he holds a J.D. from Harvard University and bachelor’s degree from Howard University. In addition to the AntriaBio board of directors, Mr. Elam sits on the board of Savara Pharmaceuticals in Austin, Texas and Aerogen, Limited in Galway, Ireland.
Sankaram Mantripragada, Ph.D., Chief Scientific Officer
Prior to joining Antriabio, Dr. Mantripragada served as VP of Research and Development of PR Pharmaceuticals, Inc. from June 2005 until October 2009. From October 2004 until June 2005, Dr. Mantripragada was an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He contributed directly to intellectual property development and product development for marketed products such as DepoCyt, DepoDur and Xsience. He is an inventor or an author of 70 publications or patents. Dr. Mantripragada served as Director, Research and Development of Guidant Corporation, now part of Abbott Vascular, from September 2003 until October 2004. Prior to that, he served as Director, Research and Development and Vice President, Scientific Development of SkyePharma from September 1992 until September 2003. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine from January 1989 until September 1994. Dr. Mantripragada obtained his PhD in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.
Keith Chun, M.D., Clinical Development
Dr. Chun joined the company in September 2012 and is also a senior member of the Konus Advisory Group. Dr. Chun has worked in a variety of healthcare organizations in various roles including most recently as the commercial diagnostics head for infectious diseases at Novartis. Earlier in his career, Dr. Chun worked at Alza Corporation and was also a consultant at Mckinsey and Company. Dr. Chun received his medical degree from Stanford University as well as a bachelor’s of science degree in chemical engineering.
Contact Info:
890 Santa Cruz Avenue
Menlo Park, CA 94025
Website: http://www.antriabio.com/
Phone: 650-241-9330
Email: info@antriabio.com
Your own due diligence and buying/selling decisions a must!
~Rig
I have been looking at more BIO plays over the last 3 months, here's one that looks to have nice potential in a huge market imo...
~Business Description:
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Our development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. Our lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
~Corporate web site:
http://antriabio.com/
~Share structure:
Number of shares of issuer’s common stock outstanding as of February 12, 2013: 40,000,000
Approximate float...5 million
~Chart:
Right near the historical low, looks like a potental move back over $2.25 based on this chart imo,
~About the lead diabetes product:
AntriaBio’s lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.
The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.
AB101’s long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.
After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.
In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.
~Pipeline:
In addition to the proprietary technology for PEGylation of insulin (AB101), AntriaBio plans to use proprietary microparticle manufacturing technology for a variety of opportunities across multiple indications.
~Recent News:
http://ir.stockpr.com/antriabio/company-news
Looks like they did a reverse merger with a forward split which is why the chart has a limited history,
~ AntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge With a Public Company
Jan 7, 2013, 9:00 AM EST
~ AntriaBio Completes Merger and Elects Board of Directors
Feb 6, 2013, 1:10 PM EST
~AntriaBio Announces Stock Ticker Symbol Change to ANTB
Feb 8, 2013, 10:44 AM EST
~AntriaBio Appoints Two Industry Leaders to Its Management Team
Feb 19, 2013, 10:37 AM EST
~Management team:
Nevan Elam, President and CEO
Mr. Elam joined the company in June 2012 and he is a Managing Director of Konus Advisory Group, a boutique healthcare firm. Mr. Elam has also been CEO of a surgical medical device company based in Europe since 2009 and prior to that he ran the Pulmonary Business Unit of Nektar Therapeutics which he sold to Novartis in 2008. Mr. Elam has spent his entire career starting, managing and advising emerging growth companies. Earlier in his career he was a corporate partner with Wilson Sonsini Goodrich & Rosati and he holds a J.D. from Harvard University and bachelor’s degree from Howard University. In addition to the AntriaBio board of directors, Mr. Elam sits on the board of Savara Pharmaceuticals in Austin, Texas and Aerogen, Limited in Galway, Ireland.
Sankaram Mantripragada, Ph.D., Chief Scientific Officer
Prior to joining Antriabio, Dr. Mantripragada served as VP of Research and Development of PR Pharmaceuticals, Inc. from June 2005 until October 2009. From October 2004 until June 2005, Dr. Mantripragada was an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He contributed directly to intellectual property development and product development for marketed products such as DepoCyt, DepoDur and Xsience. He is an inventor or an author of 70 publications or patents. Dr. Mantripragada served as Director, Research and Development of Guidant Corporation, now part of Abbott Vascular, from September 2003 until October 2004. Prior to that, he served as Director, Research and Development and Vice President, Scientific Development of SkyePharma from September 1992 until September 2003. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine from January 1989 until September 1994. Dr. Mantripragada obtained his PhD in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.
Keith Chun, M.D., Clinical Development
Dr. Chun joined the company in September 2012 and is also a senior member of the Konus Advisory Group. Dr. Chun has worked in a variety of healthcare organizations in various roles including most recently as the commercial diagnostics head for infectious diseases at Novartis. Earlier in his career, Dr. Chun worked at Alza Corporation and was also a consultant at Mckinsey and Company. Dr. Chun received his medical degree from Stanford University as well as a bachelor’s of science degree in chemical engineering.
Contact Info:
890 Santa Cruz Avenue
Menlo Park, CA 94025
Website: http://www.antriabio.com/
Phone: 650-241-9330
Email: info@antriabio.com
Your own due diligence and buying/selling decisions a must!
~Rig
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
